Navigation Links
Lithera Initiates Phase 2b Clinical Trial of LIPO-202 Targeting Aesthetic Reduction of Subcutaneous Abdominal Fat
Date:3/12/2013

SAN DIEGO, March 12, 2013 /PRNewswire/ -- Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, announced today that the first patient has been treated with LIPO-202 (Salmeterol Xinafoate for Injection) in its 500-patient Phase 2b "RESET" trial.  LIPO-202, Lithera's lead product candidate, is a novel injectable pharmaceutical product designed to produce localized reduction of subcutaneous fat.

"Initiating the RESET trial is a significant milestone for Lithera and in the development of LIPO-202 as a non-ablative treatment for the aesthetic reduction of subcutaneous abdominal fat," stated George W. Mahaffey , President and CEO of Lithera.  "Following our recent Series C financing, Lithera is focused on advancing LIPO-202 in the clinic as we see tremendous potential for the drug to address a significant opportunity in aesthetic medicine – the ability to offer a quick and minimally invasive 'lunch time' procedure with no patient down time that effectively reduces abdominal fat."  

RESET is a 500-patient, multi-center, randomized, placebo-controlled clinical trial designed to measure the effects of three different doses of LIPO-202, compared to placebo, on abdominal bulging due to excess subcutaneous fat in healthy, non-obese subjects.  Patients randomized into each of the four trial arms will receive subcutaneous injections spaced evenly across the abdomen once per week for eight weeks.  Trial endpoints include multiple qualitative and quantitative measures of bulge reduction, as well as key safety information.

"The RESET trial incorporates indication-specific objective and subjective efficacy measures, as well as a suitably large sample size in order to provide what we hope to be a very clear demonstration of LIPO-202's effectiveness and a definition of its optimal dos
'/>"/>

SOURCE Lithera, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
2. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
3. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
6. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
7. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
8. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
9. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
10. Empire Asset Management Co. Initiates Coverage on Transcept Pharmaceuticals Inc., (NASDAQ: TSPT)
11. Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 The Cardinal Health 2014 digital ... can learn about the company,s fiscal year ... the health care continuum by accessing the ... Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... chief executive officer,s letter to shareholders, the ...
(Date:10/1/2014)... NEW YORK , October 1, 2014 ... service provider for the medical industries, announced today the expansion of ... New York City . genae Americas was incorporated in ... strategically centered in one of the highest concentrations of medical innovation ... Kassab , President at genae Americas. "The expansion of genae from ...
(Date:10/1/2014)...  Express Scripts (NASDAQ: ESRX ) today ... Medicare ® Prescription Drug Plans (PDP) will offer ... WAG ) (NASDAQ: WAG ), helping ...  for their Medicare dollars. Medicare beneficiaries who ... or Choice plans for 2015 can save ...
Breaking Medicine Technology:Cardinal Health 2014 Digital Report to Shareholders Now Available 2genae Opens Offices in New York City 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4
... EAST RUTHERFORD, N.J., Nov. 1, 2011 Cambrex Corporation ... 2011 financial results will be released on Thursday, November ... The Company will host a conference call to discuss ... Conference CallWhen: , Friday, November 4, 2011 at 8:30 ...
... 2011 Takeda Global Research & Development ... Drug Administration (FDA) has assigned a Prescription Drug User ... for the review of its investigational type 2 diabetes ... combines alogliptin with pioglitazone in a single tablet.   ...
Cached Medicine Technology:Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone 2Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone 3
(Date:10/1/2014)... scientists has shown that more than 80 per cent ... , The study found that medicines called ,JAK inhibitors, ... mutation that is present in more than 80 per ... used, or are in clinical trials, for diseases including ... Bowel cancer is the second-most common cancer in Australia ...
(Date:10/1/2014)... of the human eye, the brain of a rat ... new technology, says a QUT leading robotics researcher. ... Faculty says the new study uses new computer algorithms ... buildings or tunnels. , "This is a very Frankenstein ... two halves of a thing together because we,re taking ...
(Date:10/1/2014)... Philadelphia, PA, October 1, 2014 Patients with ... treatment, have a greatly increased risk of depression. ... therapy for chronic hepatitis C virus infection causes ... Omega-3 fatty acids, more commonly known as fish ... including lowering the risk of heart disease and ...
(Date:10/1/2014)... New research suggests the adage that encourages people to ... target when it comes to exercise. When walking, staying ... distance to it appear shorter and help people walk ... compares this technique to walking while looking around the ... quality of exercise. , "People are less interested in ...
(Date:10/1/2014)... 2014 Marriagelifeinsurance.com has released a ... for retired couples. , Senior citizens can purchase ... for their loved ones. A joint policy is cheaper, ... pass away. , Life insurance can be used ... can even be purchased online, as the application process ...
Breaking Medicine News(10 mins):Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2
... , , AUSTIN, Texas, ... processing expert, ThermoGenesis Corp., to deliver the most sophisticated point ... innovative MarrowXpress(TM) (MXP(TM)) System defines a new standard for isolation ... MXP System consistently yields high (> 90%) mononuclear cell recovery ...
... Global health organization PSI helps contestants spread HIV prevention messages throughout ... 21 The Miss Universe contestants continued preparations for Sunday night,s ... condoms to test their strength and playing "Wild Fire Infection" games ... are part of an HIV peer education workshop designed by PSI ...
... , , KUALA LUMPUR, ... Technologies (ICT) is essential for modern healthcare delivery systems if ... and improve patient safety. , , (Logo: ... years, the acquisition of computer technologies by healthcare organizations has ...
... treatment to thousands who need it, experts say ... with patient and therapist texting each other in real-time ... of patients new access to much-needed treatment, researchers say. ... of research and practice involving technology-based treatments for depression ...
... , , , ... (Nasdaq: HTWR - ASX: HIN) today announced that HeartWare has surpassed ... marking an important early enrollment milestone. , , ... at the Texas Heart Institute in Houston, Texas by O.H. Frazier, ...
... N.Y. The Bioproduction Facility at Cornell University has ... vaccinethat will be used in clinical trials for patients ... was developed as a partnership between The Ludwig Institute ... trial is being conducted at New York University Medical ...
Cached Medicine News:Health News:Celling Technologies Sets New Standards With Sophisticated Adult Stem Cell Device 2Health News:Celling Technologies Sets New Standards With Sophisticated Adult Stem Cell Device 3Health News:Miss Universe Contestants Enter Condom Olympics to Tackle HIV 2Health News:Miss Universe Contestants Enter Condom Olympics to Tackle HIV 3Health News:Frost & Sullivan: Medico Legal Implications Related to the Usage of Electronic Health Record 2Health News:Frost & Sullivan: Medico Legal Implications Related to the Usage of Electronic Health Record 3Health News:Frost & Sullivan: Medico Legal Implications Related to the Usage of Electronic Health Record 4Health News:Web-Based Psychotherapy Can Work 2Health News:Web-Based Psychotherapy Can Work 3Health News:HeartWare International Surpasses 50 Implants in the US 2Health News:HeartWare International Surpasses 50 Implants in the US 3Health News:Cornell makes cancer vaccine for clinical use 2Health News:Cornell makes cancer vaccine for clinical use 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: